Abbott Laboratories (ABT) Stock Score, Valuation & Financial Research
Abbott Laboratories is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 41/100.
Quick answer for ABT
Abbott Laboratories currently has a Wall Street Score of 41/100. The stored market price is $101.96. Its financial score is 36/100. Its valuation score is 10/100. The latest WSS change is +0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Abbott Laboratories does
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vacci
ABT financial snapshot
- Wall Street Score:
- 41/100
- Current price:
- $101.96
- Market capitalization:
- $176.43B
- Revenue:
- $46.59B
- Net income:
- $5.42B
- Free cash flow:
- $7.39B
- Cash:
- $5.10B
- Total debt:
- $32.61B
- EPS:
- 3.11
- P/E ratio:
- 32.8x
- Financial score:
- 36/100
- Valuation score:
- 10/100
- Revenue score:
- 19/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $7.39B, showing positive cash generation.
- The balance sheet shows $5.10B of cash versus $32.61B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.3 points: ABT increased 0.3 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 10/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 36/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ABT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.